Indivior Pharmaceuticals, Inc. (SUPN) Current Ratio
- Current ratio · latest quarter: Value 2.08×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 2.08× | Current assets / current liabilities. $723.50M ÷ $347.38M ≈ 2.08× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 723.50M USD | Assets, Current |
| Current obligations | 347.38M USD | Liabilities, Current |
| Cash and equivalents | (m) | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | (m) | Inventory, Net |
| Payables | (m) | Accounts Payable, Current |
| Borrowing debt due within one year | (m) | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $723.50M | $347.38M | (m) | (m) | (m) | (m) | (m) | (m) | 2.08× |
| 2026-03-31 | $731.58M | $373.93M | (m) | (m) | (m) | (m) | (m) | (m) | 1.96× |
| 2025-12-31 | $644.18M | $338.17M | (m) | (m) | (m) | (m) | (m) | (m) | 1.90× |
| 2025-09-30 | $593.89M | $330.63M | (m) | (m) | (m) | (m) | (m) | (m) | 1.80× |
| 2025-06-30 | $738.87M | $286.36M | (m) | (m) | (m) | (m) | (m) | (m) | 2.58× |
| 2025-03-31 | $687.58M | $281.77M | (m) | (m) | (m) | (m) | (m) | (m) | 2.44× |
| 2024-12-31 | $686.07M | $292.40M | (m) | (m) | (m) | (m) | (m) | (m) | 2.35× |
| 2024-09-30 | $640.00M | $291.51M | (m) | (m) | (m) | (m) | (m) | (m) | 2.20× |
| 2024-06-30 | $591.00M | $308.66M | (m) | (m) | (m) | (m) | (m) | (m) | 1.91× |
| 2024-03-31 | $544.32M | $314.55M | (m) | (m) | (m) | (m) | (m) | (m) | 1.73× |
| 2023-12-31 | $493.11M | $290.20M | (m) | (m) | (m) | (m) | (m) | (m) | 1.70× |
| 2023-09-30 | $449.36M | $287.53M | (m) | (m) | (m) | (m) | (m) | (m) | 1.56× |
| 2023-06-30 | $423.54M | $252.59M | (m) | (m) | (m) | (m) | (m) | (m) | 1.68× |
| 2023-03-31 | $883.34M | $731.54M | (m) | (m) | (m) | (m) | (m) | (m) | 1.21× |
| 2022-12-31 | $734.15M | $687.96M | (m) | (m) | (m) | (m) | (m) | (m) | 1.07× |
| 2022-09-30 | $663.89M | $725.99M | (m) | (m) | (m) | (m) | (m) | (m) | 0.91× |
| 2022-06-30 | $625.12M | $735.54M | (m) | (m) | (m) | (m) | (m) | (m) | 0.85× |
| 2022-03-31 | $568.52M | $284.56M | (m) | (m) | (m) | (m) | (m) | (m) | 2.00× |
| 2021-12-31 | $601.59M | $315.38M | (m) | (m) | (m) | (m) | (m) | (m) | 1.91× |
| 2021-09-30 | $668.38M | $234.71M | (m) | (m) | (m) | (m) | (m) | (m) | 2.85× |
| 2021-06-30 | $639.24M | $283.45M | (m) | (m) | (m) | (m) | (m) | (m) | 2.26× |
| 2021-03-31 | $586.02M | $240.81M | (m) | (m) | (m) | (m) | (m) | (m) | 2.43× |
| 2020-12-31 | $630.42M | $245.11M | (m) | (m) | (m) | (m) | (m) | (m) | 2.57× |
| 2020-09-30 | $552.01M | $299.61M | (m) | (m) | (m) | (m) | (m) | (m) | 1.84× |
| 2020-06-30 | $557.15M | $269.28M | (m) | (m) | (m) | (m) | (m) | (m) | 2.07× |
| 2020-03-31 | $557.05M | $168.34M | (m) | (m) | (m) | (m) | (m) | (m) | 3.31× |
| 2019-12-31 | $472.64M | $160.59M | (m) | (m) | (m) | (m) | (m) | (m) | 2.94× |
| 2019-09-30 | $427.08M | $149.72M | (m) | (m) | (m) | (m) | (m) | (m) | 2.85× |
| 2019-06-30 | $390.91M | $143.97M | (m) | (m) | (m) | (m) | (m) | (m) | 2.72× |
| 2019-03-31 | $419.97M | $151.71M | (m) | (m) | (m) | (m) | (m) | (m) | 2.77× |
| 2018-12-31 | $493.49M | $161.35M | (m) | (m) | (m) | (m) | (m) | (m) | 3.06× |
| 2018-09-30 | $390.56M | $138.35M | (m) | (m) | (m) | (m) | (m) | (m) | 2.82× |
| 2018-06-30 | $284.52M | $103.93M | (m) | (m) | (m) | (m) | (m) | (m) | 2.74× |
| 2018-03-31 | $583.25M | $119.09M | (m) | (m) | (m) | (m) | (m) | (m) | 4.90× |
| 2017-12-31 | $228.45M | $123.00M | (m) | (m) | (m) | (m) | (m) | (m) | 1.86× |
| 2017-09-30 | $191.33M | $104.96M | (m) | (m) | (m) | (m) | (m) | (m) | 1.82× |
| 2017-06-30 | $165.49M | $85.52M | (m) | (m) | (m) | (m) | (m) | (m) | 1.94× |
| 2017-03-31 | $149.76M | $82.00M | (m) | (m) | (m) | (m) | (m) | (m) | 1.83× |
| 2016-12-31 | $151.40M | $80.74M | (m) | (m) | (m) | (m) | (m) | (m) | 1.88× |
| 2016-09-30 | $138.20M | $71.65M | (m) | (m) | (m) | (m) | (m) | (m) | 1.93× |
| 2016-06-30 | $114.14M | $67.51M | (m) | (m) | (m) | (m) | (m) | (m) | 1.69× |
| 2016-03-31 | $93.95M | $55.53M | (m) | (m) | (m) | (m) | (m) | (m) | 1.69× |
| 2015-12-31 | $105.95M | $56.93M | (m) | (m) | (m) | (m) | (m) | (m) | 1.86× |
| 2015-09-30 | $102.52M | $43.69M | (m) | (m) | (m) | (m) | (m) | (m) | 2.35× |
| 2015-06-30 | $105.70M | $36.63M | (m) | (m) | (m) | (m) | (m) | (m) | 2.89× |
| 2015-03-31 | $101.45M | $27.51M | (m) | (m) | (m) | (m) | (m) | (m) | 3.69× |
| 2014-12-31 | $108.73M | $28.12M | (m) | (m) | (m) | (m) | (m) | (m) | 3.87× |
| 2014-09-30 | $102.80M | $22.13M | (m) | (m) | (m) | (m) | (m) | (m) | 4.65× |
| 2014-06-30 | $71.98M | $19.19M | (m) | (m) | (m) | (m) | (m) | (m) | 3.75× |
| 2014-03-31 | $79.93M | $27.10M | (m) | (m) | (m) | (m) | (m) | (m) | 2.95× |
| 2013-12-31 | $97.16M | $26.40M | (m) | (m) | (m) | (m) | (m) | (m) | 3.68× |
| 2013-09-30 | $102.86M | $25.07M | (m) | (m) | (m) | (m) | (m) | (m) | 4.10× |
| 2013-06-30 | $110.62M | $16.02M | (m) | (m) | (m) | (m) | (m) | (m) | 6.90× |
| 2013-03-31 | $76.33M | $27.01M | (m) | (m) | (m) | (m) | (m) | (m) | 2.83× |
| 2012-12-31 | $91.46M | $22.98M | (m) | (m) | (m) | (m) | (m) | (m) | 3.98× |
| 2012-09-30 | $62.89M | $24.59M | (m) | (m) | (m) | (m) | (m) | (m) | 2.56× |
| 2012-06-30 | $77.81M | $21.88M | (m) | (m) | (m) | (m) | (m) | (m) | 3.56× |
| 2012-03-31 | $38.42M | $19.91M | (m) | (m) | (m) | (m) | (m) | (m) | 1.93× |
| 2011-12-31 | $49.40M | $18.77M | (m) | (m) | (m) | (m) | (m) | (m) | 2.63× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |